Recent Headlines
Mirror Biologics, Inc. Appoints Elizabeth Czerepak as Chief Financial Officer and VP Corporate Development
Mirror Biologics, Inc., a clinical stage biopharmaceutical company announces the appointment of Elizabeth Adkins Czerepak as Chief Financial Officer (CFO) and Vice President of Corporate Development effective April 15, 2024. Ms. Czerepak has served as CFO of several biotechnology companies over... - April 18, 2024 - Mirror Biologics, Inc.
Huntington Study Group Launches Project AWARE 2.0 Observational Study
The Huntington Study Group® and HSG Clinical Research, Inc. (together, “HSG”) are pleased to announce the launch of Project AWARE 2.0, an observational study developed in collaboration with Roche Products Limited and Genentech to understand and improve Awareness, Willingness, and... - April 10, 2024 - Huntington Study Group
FuseBio Presents New Data at AACR: Targeting a Functionally-Selective IL-18 (F-18) to PD-1: A Next Generation Checkpoint Inhibitor with Enhanced Anti-Tumor Activity
FuseBio's unique attenuation mechanism renders IL-18, a functionally selective IL-18, resistant to IL-18BP and 1 million percent less active in circulation and yet still retain nearly full activity when targeted to PD-1+/IL-18R+ cells, the key functional immune cells in tumors. It is designed to retain full activity of PD-1 checkpoint blockade and simultaneously deliver a functionally selective IL-18 (F-18) to preserve and enhance the anti-tumor activity of immune cells. - April 09, 2024 - Fuse Biotherapeutics
Parvus Announces Collaboration with AbbVie to Develop IBD Therapies Based on the Parvus Navacim Platform Technology
The collaboration will combine AbbVie’s expertise in Immunology with Parvus’ innovative Navacim™ regulatory T cells (Treg) immune tolerization platform technology to develop therapies for Inflammatory Bowel Disease Parvus Therapeutics announced today that it has entered into an... - March 20, 2024 - Parvus Therapeutics U.S., Inc.
iView Therapeutics Inc. Announced FDA’s Clearance of IND Application for IVW-1001 Ophthalmic Eyelid Wipe to Treat Signs and Symptoms of Dry Eye Disease
iView Therapeutics Inc., a clinical stage biotechnology company dedicated to advancing innovative treatments for ocular diseases, announces that the U.S. Food and Drug Administration (FDA) cleared iView’s Investigational New Drug (IND) application to for the initiation of a Phase 1/2 clinical... - March 11, 2024 - iView Therapeutics Inc.
IVIEW Announces Presentation of Positive Topline Results in Phase II Clinical Study of IVIEW-1201 for the Treatment of Bacterial Conjunctivitis at ARVO 2024
IVIEW Therapeutics Inc. announces to present the positive topline result in the Phase II Clinical Study of IVIEW-1201 for the Treatment of Bacterial Conjunctivitis in the upcoming 2024 ARVO (The Association for Research in Vision and Ophthalmology) national meeting in Seattle, WA. The Presentation... - February 28, 2024 - iView Therapeutics Inc.
Cayman Chemical Introduces LipidLaunch™, Expands Portfolio of Lipid Nanoparticle Research Tools to Support Advances in RNA Therapies
Cayman Chemical introduces the latest addition to the company’s portfolio of lipid nanoparticle (LNP) research tools for academic, pharma, and biotech researchers worldwide. The LipidLaunch™ product line helps researchers pursue LNPs for the delivery of nucleic acid therapies in untold health applications, ranging from vaccine development to cancer and cell or gene therapies. - February 22, 2024 - Cayman Chemical Company
Biopharmaceutical Sponsor Interaction with Clinical Site Networks Pulse Report
Sponsor Outsourcing Dollars May Shift to Clinical Site Networks, Transforming the CRO Relationship - February 13, 2024 - Life Science Strategy Group, LLC
Microvascular Therapeutics Welcomes Thom Tulip as Chief Business Officer
Microvascular Therapeutics Inc. (MVT), a clinical-stage biotech company at the forefront of developing the next generation of microbubbles unlocking the therapeutic potential of ultrasound, proudly announces the appointment of Dr Thom Tulip as their new Chief Business Officer. In this pivotal role, Dr Tulip will lead capital raises to propel MVT's cutting-edge technologies into the market. - February 10, 2024 - Microvascular Therapeutics, Inc.
Creative Diagnostics Launches Aflatoxin Test Reagents to Ensure Food Safety
Creative Diagnostics has announced the launch of Aflatoxin Test Reagents to detect harmful mycotoxins in various food products. - February 04, 2024 - Creative Diagnostics
Creative Diagnostics Launches Serum Plate Agglutination Test for In Vitro Detection of Multiple Pathogens
Creative Diagnostics is pleased to announce the launch of its Serum Plate Agglutination Test. - February 04, 2024 - Creative Diagnostics
Creative Diagnostics Announces New AAV Reagent Solutions for Gene Therapy
Creative Diagnostics has announced its extensive portfolio of AAV Reagent Solutions to support researchers. - February 04, 2024 - Creative Diagnostics
Patient Experience and Satisfaction with Electronic Consent, Onboarding, and Diaries in Clinical Trials Report
New Market Research Shows Different Patient Preferences for Electronic Diaries - January 31, 2024 - Life Science Strategy Group, LLC
Creative Diagnostics Launches Rapid Robenidine Test Reagents for the Analysis of Anticoccidial Residues
Creative Diagnostics has announced the launch of its new Robenidine Test Reagents for the detection of robenidine residues. - January 26, 2024 - Creative Diagnostics
Creative Diagnostics Announces MDT Services for Measuring Antibacterial Effectiveness
Creative Diagnostics has announced new Minimum Doubling Time (MDT) services to measure the effectiveness of antibacterial compounds. - January 26, 2024 - Creative Diagnostics
Creative Diagnostics Launches New P53 and Tp53 Antibodies for Cancer Research
Creative Diagnostics has announced P53 and TP53 antibodies and solutions to support cancer research. - January 26, 2024 - Creative Diagnostics
Huntington Study Group Announces 2024 Annual Meeting
The Huntington Study Group® (HSG), together with its wholly owned subsidiary, HSG Clinical Research, Inc., a world leader in conducting clinical trials for Huntington’s disease (HD), is pleased to announce that its annual meeting for 2024 is slated to take place from November 6-9 at the... - January 22, 2024 - Huntington Study Group
Impact of the In Vitro Diagnostic Regulation on Clinical Trials in the EU and CRO Outsourcing Report
IVDR Delays Driving Trial Sponsors to Actively Seek Alternative Site and CRO Outsourcing Strategies - January 17, 2024 - Life Science Strategy Group, LLC
NuvOx Pharma Announces Issuance of a New Patent
NuvOx Pharma has been issued US Patent No. 11,857,627, entitled “Fractionated Radiotherapy and Chemotherapy with an Oxygen Therapeutic.” - January 14, 2024 - NuvOx Pharma
Huntington Study Group and Roche Collaborate on GENERATION HD2 Study
The Huntington Study Group together with its wholly-owned clinical research organization, HSG Clinical Research, Inc. (HSGCR), is pleased to announce a collaboration with Roche-Genentech to optimize our collective experiences in Huntington’s disease (HD) clinical research. Together we are... - December 13, 2023 - Huntington Study Group
Creative Diagnostics Launches Macrophage Migration Inhibitory Factor Reagents for Research Applications
Creative Diagnostics has launched a portfolio of Macrophage Migration Inhibitory Factor (MIF) reagents for researchers. - December 13, 2023 - Creative Diagnostics
Breakthrough Study by Microvascular Therapeutics Reveals Fibrin-Targeted Phase Shift Microbubbles as Promising Solution for Microvascular Obstruction
Microvascular Therapeutics, a trailblazing healthcare research and development company, announces a groundbreaking study on the treatment of Microvascular Obstruction (MVO) through sonoreperfusion. The study, led by Dr. John J. Pacella and his team at the Center for Ultrasound Molecular Imaging and... - December 13, 2023 - Microvascular Therapeutics, Inc.
Microvascular Therapeutics Selected as a Participant in the 2023 H7 BioCapital Accelerator Program
Microvascular Therapeutics (MVT), a clinical stage biopharma pioneering the potential of ultrasound in diagnostics and theranostics, has been selected to join the prestigious H7 Healthcare Accelerator 2023 Cohort, powered by H7 BioCapital. The program is renowned for providing a dynamic platform... - December 13, 2023 - Microvascular Therapeutics, Inc.
Creative Diagnostics Announces New Test Reagents for Dapsone
Creative Diagnostics has announced the launch of a range of new reagents for the analysis of Dapsone in food. - December 13, 2023 - Creative Diagnostics
Creative Diagnostics Announces New MBC Assay for Antibacterial Testing
Creative Diagnostics has announced the launch of its new Minimum Bactericidal Concentration (MBC) Assay for antibacterial testing. - December 13, 2023 - Creative Diagnostics
FF Biotherapeutics Announces Search for Angel Investment to Revolutionize Immunotherapy and Vaccine Development
FF Biotherapeutics, a pioneering biotech startup at the forefront of immunotherapy and vaccine development, today announced its active pursuit of Angel investment. This critical funding round aims to propel the development of its groundbreaking Synthetic Standardized Convalescent Plasma (SSCP) and... - November 29, 2023 - FF Biotherapeutics
Huntington Study Group® Holds 30th Annual Meeting
The Huntington Study Group® (HSG®), a world leader in conducting clinical trials and providing educational programming for Huntington’s disease (HD), recently held its 30th annual meeting, HSG 2023, November 2-4 in Phoenix, AZ. Hundreds of scientists, industry partners, HSG research... - November 21, 2023 - Huntington Study Group
Creative Diagnostics Launches Carbamazepine Test Reagents
Creative Diagnostics has announced the release of its new line of Carbamazepine Test Reagents. - November 04, 2023 - Creative Diagnostics
Creative Diagnostics Launches Minimum Inhibitory Concentration Testing Services
Creative Diagnostics has recently launched a series of new Minimum Inhibitory Concentration (MIC) assay services for researchers. - November 04, 2023 - Creative Diagnostics
Creative Diagnostics Announces New CLDN6 Solutions for Cancer Research
Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has launched a range of antibodies, antigens and kits against CLDN6 to support researchers worldwide in preclinical and clinical safety/efficacy testing. CLDN6 may be involved in the development and... - November 04, 2023 - Creative Diagnostics
Microvascular Therapeutics Receives $3.98M Award from Department of Defense for Its Cardiovascular Product
Microvascular Therapeutics (MVT), a clinical stage biotechnology company based in Tucson, AZ, was recently awarded a $3.98M FY22 Technology/Therapeutic Development – Funding Level 2 grant from the Congressionally Directed Medical Research Programs (CDMRP). Emmanuelle Meuillet, Chief... - October 18, 2023 - Microvascular Therapeutics, Inc.
Huntington Study Group® Observational Pilot Study Shows HSG’s myHDstory® Platform Reaches the Unreachable
The Huntington Study Group® (HSG) together with its wholly owned subsidiary, HSG Clinical Research, Inc. (HSGCR), a world leader in conducting clinical trials for Huntington’s disease (HD), today announces that the pilot observational study on their innovative online direct-to-patient... - October 16, 2023 - Huntington Study Group
Creative Diagnostics Launches New Anti-Small Molecule Label Antibodies to Facilitate NALFIA Development
Creative Diagnostics has recently announced a series of new Anti-Small Molecule Label Antibodies to facilitate the development of NALFIA. - October 15, 2023 - Creative Diagnostics
Creative Diagnostics Launches New Azaperone Test Reagents for Research Applications
Creative Diagnostics has announced the release of its new line of Azaperone Test Reagents. - October 15, 2023 - Creative Diagnostics
Creative Diagnostics Launches Checkerboard Assay Services
Creative Diagnostics has recently announced the launch of its new Checkerboard Assay services to support researchers. - October 15, 2023 - Creative Diagnostics
NuvOx Therapeutics Wins Most Fundable Company by Pepperdine Graziadio Business School
NuvOx Therapeutics (“NuvOx”) is delighted to announce that it achieved the Gold Level recognition on the Pepperdine Graziadio Business School's sixth annual Most Fundable Companies® List. NuvOx Therapeutics competed against over 3,000 of early-stage US companies to be named one of 17 companies in total. - October 11, 2023 - NuvOx Pharma
Cayman Chemical Introduces a New Tool to Study Protein-Lipid Interactions
Cayman LipiDOT Strips™ are a simple tool for the rapid identification of protein-lipid interactions. Researchers can screen a protein of interest against 22 biologically relevant lipids in one assay in a single day at a lower price compared with existing commercial options. - October 04, 2023 - Cayman Chemical Company
NuvOx Closed Oversubscribed Convertible Notes
NuvOx Therapeutics (“NuvOx”) announced that it has closed an oversubscribed convertible notes round, raising approximately $7M out of the originally planned $5M. In this raise, NuvOx leverages large angel groups nationwide, and 11 angel groups joined the round. As a result, NuvOx... - September 27, 2023 - NuvOx Pharma
National Brain Tumor Society to Launch Campaigns Elevating the Necessity of Clinical Trials and Biomarker Testing Access, Guiding More Informed Treatment Decisions
Joint initiatives aim to help patients and families navigate the era of precision medicine in cancer care. - September 13, 2023 - National Brain Tumor Society
Creative Diagnostics Launches Antimicrobial Synergy Testing Services
Creative Diagnostics has recently launched a series of Antimicrobial Synergy Testing Services to the reserch community. - September 06, 2023 - Creative Diagnostics
Creative Diagnostics Introduces New ELISA Kits to Accelerate Autoimmunity Research
Creative Diagnostics has announced a series of new ELISA Kits to assist researchers in studing the mechanisms of autoimmunity. - September 06, 2023 - Creative Diagnostics
NuvOx Announces Publication of Research Article in Cancer Research Communication
NuvOx Pharma announced publication of a research article, “Dodecafluoropentane Emulsion as a Radiosensitizer in Glioblastoma Multiforme” in Cancer Research Communications. https://aacrjournals.org/cancerrescommun/article/3/8/1607/728499. Evan Unger, MD, President and CEO of NuvOx,... - September 01, 2023 - NuvOx Pharma
Huntington Study Group Welcomes FDA Approval of New Drug for Chorea in Huntington’s Disease
The Huntington Study Group (HSG) together with its wholly owned subsidiary, HSG Clinical Research, Inc., a world leader in clinical trials for Huntington’s disease (HD), today shares that the Phase 3 pivotal KINECT®-HD study conducted by HSG in collaboration with Neurocrine Biosciences,... - August 18, 2023 - Huntington Study Group
Huntington Study Group Announces Positive Topline Results for Virtual Unified Huntington’s Disease Rating Scale® (vUHDRS®) Study
The Huntington Study Group (HSG) together with its wholly owned subsidiary, HSG Clinical Research, Inc., a world leader in conducting clinical trials for Huntington’s disease (HD), today announces positive topline results from its Virtual Unified Huntington’s Disease Rating Scale®... - August 14, 2023 - Huntington Study Group
Creative Diagnostics Announces New Reagents for Bioanalysis of Antibody Drug Conjugates
Creative Diagnostics has announced a series of new reagent solutions to assist researchers in the bioanalysis of ADCs. - August 06, 2023 - Creative Diagnostics
Creative Diagnostics Announces New Antimicrobial Susceptibility Testing Services
Creative Diagnostics announced the launch of its new Antimicrobial Susceptibility Testing (AST) services. - August 06, 2023 - Creative Diagnostics
Huntington Study Group and CHDI Foundation Collaborate on Enroll-HD
HSG Clinical Research, Inc. - the Huntington Study Group’s clinical research organization (CRO) and wholly owned subsidiary (collectively referred to here as HSG) - has begun providing CRO services for CHDI Foundation’s Enroll-HD observational study and clinical research platform in the... - July 25, 2023 - Huntington Study Group
Cayman and Navinci Announce Strategic Partnership, Expanding Access to Next-Generation Tools for Spatial Proteomics
Cayman and Navinci have partnered to bring next-generation proximity ligation-based solutions for spatial proteomics to US and Canada-based researchers. - July 13, 2023 - Cayman Chemical Company
Paras Biopharma (Biologics CDMO) Announces Industry Leading Scale-up Development & Production Process of an “Onco-Immunology Fc-fusion Biologic”
Paras Biopharma (Biologics CDMO) Finland team is pleased to announce that its extensive efforts have resulted in the successful scale-up, optimization & development of a biologically-active onco-immunology, “peptide FC-fusion” biologic. - July 12, 2023 - Paras Biopharmaceuticals Finland Oy
Creative Diagnostics Launches New Reagent Solutions for Herpesvirus Research
Creative Diagnostics has announced the launch of new reagent solutions for herpesvirus research. - July 07, 2023 - Creative Diagnostics